<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8180">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839604</url>
  </required_header>
  <id_info>
    <org_study_id>D5660C00001</org_study_id>
    <secondary_id>ISIS 481464</secondary_id>
    <nct_id>NCT01839604</nct_id>
  </id_info>
  <brief_title>A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Isis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>South Korea: Institutional Review Board</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Japan: Institutional Review Board</authority>
    <authority>Taiwan: Institutional Review Board</authority>
    <authority>Taiwan: Department of Health</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Hong Kong: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability,
      pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with
      advanced/metastatic hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability,
      Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients with
      Advanced/Metastatic Hepatocellular Carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigation of the safety and tolerability of AZD9150 when given intravenously to patients with hepatocellular carcinoma and determine a recommended phase II dose and schedule (RP2D) by evaluating dose limiting toxicities occurred during cycle 1.</measure>
    <time_frame>Assessed up to12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>For routine safety monitoring, visit scheduled on Screening, Cycle1Day1, 3, 5, 8, 15 and 22, Day1, 8, 15 and 22 of every Cycle until study discontinuation and 28-day follow up,assessed up to 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics (PK) of AZD9150 (following a single and multiple administrations in patients with HCC by determining Cmax, using the plasma concentration data.</measure>
    <time_frame>8 times of PK sampling on Day1 of Cycle1 and once on Day3,5,8,15 and 22 of Cycle1 and on Day1 of Cycle2-5. Additional 6 patients in Japan; 8 times of PK sampling on Day1 of Cycle1 and once on Day3,5,8 and 15 of Cycle1 and 9 times on Day22 of Cycle1.</time_frame>
    <safety_issue>No</safety_issue>
    <description>8 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24 hours post-dose) on Day1 of Cycle1, once (pre-dose) on Day 3, 5, 8, 15 and 22 of Cycle1 and Day1 of Cycle2-5. For additional 6 patients in Japan, 8 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24 hours post-dose) on Day1 of Cycle1, once (pre-dose) on Day 3, 5, 8 and 15 of Cycle1 and 9 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24, 72 hours post-dose) on Day22 Cycle1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obtaining of a preliminary assessment of the anti-tumour activity of AZD9150 by evaluation of tumour response.</measure>
    <time_frame>Every 6 weeks, assessed up to 12 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumour response assessment by modified Response Evaluation Criteria in Solid Tumours (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics (PK) of AZD9150 (following a single and multiple administrations in patients with HCC by determining Tmax, using the plasma concentration data.</measure>
    <time_frame>8 times of PK sampling on Day1 of Cycle1 and once on Day3,5,8,15 and 22 of Cycle1 and on Day1 of Cycle2-5. Additional 6 patients in Japan; 8 times of PK sampling on Day 1 of Cycle 1 and once on Day3,5,8 and 15 of Cycle 1 and 9 times on Day 22 of cycle1.</time_frame>
    <safety_issue>No</safety_issue>
    <description>8 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24 hours post-dose) on Day1 of Cycle1, once (pre-dose) on Day 3, 5, 8, 15 and 22 of Cycle1 and Day1 of Cycle2-5 For additional 6 patients in Japan, 8 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24 hours post-dose) on Day1 of Cycle1, once (pre-dose) on Day 3, 5, 8 and 15 of Cycle1 and 9 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24, 72 hours post-dose) on Day22 Cycle1.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Advanced Adult Hepatocellular Carcinoma</condition>
  <condition>Hepatocellular Carcinoma Metastatic</condition>
  <arm_group>
    <arm_group_label>AZD9150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9150</intervention_name>
    <description>Intravenous infusion over 3 hours.</description>
    <arm_group_label>AZD9150</arm_group_label>
    <other_name>ISIS 481464</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged at least 18 years. Patient from Japan and Taiwan aged at least 20 years

          -  Histologically or cytologically confirmed HCC (with the exception of fibrolamellar
             carcinoma or mixed variants of HCC with fibrolamellar histology OR clinically
             diagnosed HCC for patients with difficulty in obtaining histological diagnosis)

          -  Relapsed, refractory, intolerant or unlikely to benefit from sorafenib (for example
             due to comorbidity)

          -  Metastatic or locally advanced meeting ANY of the criteria below:

          -  HCC not suitable to receive local therapy

          -  Disease recurred or was refractory to last therapy (local or systemic)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no
             deterioration over the previous 2 weeks and minimum life expectancy of 8 weeks

        Exclusion Criteria:

          -  More than 2 prior systemic treatments for HCC

          -  Prior grade 3 hematologic toxicity related to treatment with a JAK or STAT3 inhibitor

          -  Presence of hepatic encephalopathy within 4 weeks of 1st dose

          -  Uncontrolled massive ascites

          -  High likelihood of bleeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Neumann, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information</last_name>
    <phone>800-236-9933</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hongkong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kashiwa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osakasayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Child-Pugh A to B7,</keyword>
  <keyword>Advanced/Metastatic Hepatocellular Carcinoma,</keyword>
  <keyword>AZD9150,</keyword>
  <keyword>Antisense Oligonucleotide Inhibitor of STAT3</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
